Beran Azizullah, Altorok Nehaya, Srour Omar, Malhas Saif-Eddin, Khokher Waleed, Mhanna Mohammed, Ayesh Hazem, Aladamat Nameer, Abuhelwa Ziad, Srour Khaled, Mahmood Asif, Altorok Nezam, Taleb Mohammad, Assaly Ragheb
Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.
Department of Neurology, University of Toledo, Toledo, OH 43606, USA.
J Clin Med. 2022 Apr 1;11(7):1971. doi: 10.3390/jcm11071971.
The crystalloid fluid of choice in sepsis remains debatable. We aimed to perform a comprehensive meta-analysis to compare the effect of balanced crystalloids (BC) vs. normal saline (NS) in adults with sepsis. A systematic search of PubMed, EMBASE, and Web of Sciences databases through 22 January 2022, was performed for studies that compared BC vs. NS in adults with sepsis. Our outcomes included mortality and acute kidney injury (AKI), need for renal replacement therapy (RRT), and ICU length of stay (LOS). Pooled risk ratio (RR) and mean difference (MD) with the corresponding 95% confidence intervals (CIs) were obtained using a random-effect model. Fifteen studies involving 20,329 patients were included. Overall, BC showed a significant reduction in the overall mortality (RR 0.88, 95% CI 0.81-0.96), 28/30-day mortality (RR 0.87, 95% CI 0.79-0.95), and AKI (RR 0.85, 95% CI 0.77-0.93) but similar 90-day mortality (RR 0.96, 95% CI 0.90-1.03), need for RRT (RR 0.91, 95% CI 0.76-1.08), and ICU LOS (MD -0.25 days, 95% CI -3.44, 2.95), were observed between the two groups. However, subgroup analysis of randomized controlled trials (RCTs) showed no statistically significant differences in overall mortality (RR 0.92, 95% CI 0.82-1.02), AKI (RR 0.71, 95% CI 0.47-1.06), and need for RRT (RR 0.71, 95% CI 0.36-1.41). Our meta-analysis demonstrates that overall BC was associated with reduced mortality and AKI in sepsis compared to NS among patients with sepsis. However, subgroup analysis of RCTs showed no significant differences in both overall mortality and AKI between the groups. There was no significant difference in the need for RRT or ICU LOS between BC and NS. Pending further data, our study supports using BC over NS for fluid resuscitation in adults with sepsis. Further large-scale RCTs are necessary to validate our findings.
脓毒症中晶体液的最佳选择仍存在争议。我们旨在进行一项全面的荟萃分析,以比较平衡晶体液(BC)与生理盐水(NS)对脓毒症成年患者的影响。通过对PubMed、EMBASE和Web of Sciences数据库进行系统检索,截至2022年1月22日,查找比较BC与NS用于脓毒症成年患者的研究。我们的观察指标包括死亡率、急性肾损伤(AKI)、肾脏替代治疗(RRT)需求以及重症监护病房(ICU)住院时间(LOS)。采用随机效应模型获得合并风险比(RR)和平均差(MD)以及相应的95%置信区间(CI)。纳入了15项涉及20329例患者的研究。总体而言,BC组在总死亡率(RR 0.88,95%CI 0.81 - 0.96)、28/30天死亡率(RR 0.87,95%CI 0.79 - 0.95)和AKI发生率(RR 0.85,95%CI 0.77 - 0.93)方面显著降低,但两组在90天死亡率(RR 0.96,95%CI 0.90 - 1.03)、RRT需求(RR 0.91,95%CI 0.76 - 1.08)和ICU住院时间(MD -0.25天,95%CI -3.44,2.95)方面相似。然而,随机对照试验(RCT)的亚组分析显示,在总死亡率(RR 0.92,95%CI 0.82 - 1.02)、AKI发生率(RR 0.71,95%CI 0.47 - 1.06)和RRT需求(RR 0.71,95%CI 0.36 - 1.41)方面无统计学显著差异。我们的荟萃分析表明,与NS相比,脓毒症患者总体上BC与死亡率降低和AKI发生率降低相关。然而,RCT的亚组分析显示两组在总死亡率和AKI发生率方面均无显著差异。BC与NS在RRT需求或ICU住院时间方面无显著差异。在有更多数据之前,我们的研究支持在脓毒症成年患者的液体复苏中使用BC而非NS。需要进一步的大规模RCT来验证我们的研究结果。